Metabolic Weight Loss Stack — Retatrutide & MOTS-C
Metabolic Weight Loss Stack — Retatrutide & MOTS-C - Image 2
Metabolic Weight Loss Stack — Retatrutide & MOTS-C - Image 3
Research Use Only

Metabolic Weight Loss Stack — Retatrutide & MOTS-C

(7 customer reviews)
€ 104
€ 40

Price range: € 50 through € 130

Free EU Shipping
Secure Checkout
Full COA Included
Ships within 24h
≥99% HPLC Purity Research Grade Cold-Chain Shipped Research Use Only
Categories: , Tags: , , , , , ,

Metabolic Weight Loss Stack — Retatrutide & MOTS-C: The Most Advanced Dual-Pathway Metabolic Research Protocol

The Metabolic Weight Loss Stack pairs Retatrutide — the first GIP/GLP-1/glucagon triple agonist to demonstrate over 24% body weight reduction in Phase II clinical trials, surpassing all previously tested pharmacological agents — with MOTS-C, the mitochondria-encoded exercise mimetic that activates AMPK independently of the incretin axis. The combination creates a research model targeting metabolic dysfunction through two entirely separate molecular pathways: central neuroendocrine appetite suppression and energy expenditure (Retatrutide) and peripheral mitochondrial energy sensing and glucose disposal (MOTS-C).

Retatrutide (LY3437943): The Triple Incretin Agonist

What Is Retatrutide?

Retatrutide (development code LY3437943) is a synthetic acylated peptide analogue engineered by Eli Lilly & Company as a triple agonist of three metabolic hormone receptors simultaneously: the GIP receptor (GIPR), the GLP-1 receptor (GLP-1R), and the glucagon receptor (GCGR). It builds upon the dual GIP/GLP-1 mechanism of tirzepatide (Mounjaro/Zepbound) — itself the highest-performing approved weight loss drug — by adding glucagon receptor co-agonism, which expands metabolic effects to include dramatically increased energy expenditure and hepatic fat mobilisation, two mechanisms absent or weak in dual-agonist approaches.

Mechanism of Action

  • GLP-1R agonism: In the hypothalamic arcuate (ARC) and paraventricular nuclei (PVN), GLP-1R activation suppresses appetite by reducing neuropeptide Y (NPY) and agouti-related peptide (AgRP) — the primary orexigenic signals. In the gut, it slows gastric emptying, dramatically prolonging satiety duration. In pancreatic beta cells, it drives glucose-dependent insulin secretion with no hypoglycaemia risk at euglycaemia
  • GIPR agonism: GIP receptors in adipose tissue and the CNS contribute to the overall weight loss effect when co-stimulated with GLP-1R — a synergy not yet fully mechanistically elucidated, but consistently demonstrated to exceed either agonist alone. GIP also modulates bone metabolism, kidney function, and cardiovascular physiology
  • GCGR agonism — the key differentiator: Glucagon receptor activation drives hepatic glycogenolysis, increases fatty acid β-oxidation via CPT-1 upregulation, induces thermogenesis in brown adipose tissue (BAT) via UCP-1 (uncoupling protein-1), and activates a strong satiety signal through vagal afferents. Most critically, GCGR agonism significantly increases resting energy expenditure — addressing the metabolic adaptation (compensatory metabolic slowing) that limits long-term weight loss with appetite suppression alone
  • Hepatic fat reduction: Via GCGR-driven cAMP elevation in hepatocytes, retatrutide markedly reduces liver fat (steatosis) — making it simultaneously the most potent pharmacological research tool for both obesity and non-alcoholic steatohepatitis (NASH) models

Phase II Clinical Trial Data

Retatrutide has produced the most impressive Phase II weight loss data of any pharmacological agent in the history of obesity research:

  • NEJM Phase II trial (2023): Adults with obesity receiving retatrutide 12mg weekly achieved a mean weight reduction of 24.2% of body weight at 48 weeks — surpassing semaglutide (~15%), tirzepatide (~22%), and approaching outcomes previously observed only with bariatric surgery (Jastreboff AM et al., 2023 — N Engl J Med)
  • Dose-response relationship: 4mg group: −17.5% body weight; 8mg group: −22.8%; 12mg group: −24.2%. Responder rate (≥5% loss) at highest dose: >96%
  • Metabolic parameters: Fasting glucose −28 mg/dL, HbA1c −1.6%, triglycerides −30%, blood pressure −4/−3 mmHg; increased HDL cholesterol
  • Lean mass preservation: Unlike severe caloric restriction, retatrutide maintained lean-to-fat mass ratio — a critical research variable for understanding quality of weight loss vs. quantity
  • NASH model (Phase II): Significant reductions in liver fat content (MRI-PDFF) and fibrosis biomarkers, establishing retatrutide as the leading research compound for cardiometabolic-hepatic axis studies
  • Type 2 diabetes: Landmark Lancet 2023 trial: mean HbA1c reduction of 2.02% vs. 0.27% placebo at 24 weeks in T2D patients — with associated weight loss of 16.94% vs. 2.22% in placebo group (Rosenstock J et al., 2023 — Lancet)

Retatrutide Research References

  1. Jastreboff AM et al. “Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.” N Engl J Med, 2023;389(6):514–526.
  2. Rosenstock J et al. “Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes.” Lancet, 2023;402(10401):529–544.
  3. Coskun T et al. “LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss.” Cell Metab, 2022;34(9):1234–1247.
  4. Cusi K et al. “Retatrutide for NASH — Phase 2 results.” EASL Congress, 2023.

MOTS-C: The Mitochondrial AMPK Activator

What Is MOTS-C?

MOTS-C (Mitochondrial Open reading frame of the 12S rRNA type-c) is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA region — previously considered non-coding. Discovered in 2015 by Lee et al. at the University of Southern California, MOTS-C represents a fundamentally new paradigm in metabolic regulation: a retrograde mitochondrial-to-nuclear signal that coordinates systemic energy homeostasis in response to mitochondrial status. Its plasma levels decline with age and obesity, inversely correlating with insulin resistance, metabolic syndrome severity, and cardiovascular risk.

Mechanism of Action

  • AMPK activation via AICAR: MOTS-C inhibits MTHFD1 in the folate cycle, causing accumulation of AICAR (5-aminoimidazole-4-carboxamide ribonucleotide) — an endogenous AMP-mimetic that phosphorylates AMPK at Thr172 via LKB1 — functionally mimicking prolonged aerobic exercise at the molecular level
  • Direct nuclear translocation: Under metabolic stress, MOTS-C translocates directly to the nucleus where it interacts with ARE (antioxidant response elements) via Nrf2 and suppresses NF-κB inflammatory signalling — a mechanism entirely independent of AICAR/AMPK
  • GLUT4 translocation: AMPK-dependent phosphorylation of TBC1D1 and AS160 drives GLUT4 vesicle fusion with the sarcolemma — increasing skeletal muscle glucose uptake independently of insulin receptor activation
  • Enhanced β-oxidation: AMPK phosphorylates and inhibits ACC (acetyl-CoA carboxylase), reducing malonyl-CoA, relieving CPT-1 (carnitine palmitoyltransferase-1) inhibition, and dramatically increasing mitochondrial long-chain fatty acid import for β-oxidation
  • mTORC1 suppression via TSC2/Raptor: AMPK phosphorylates TSC2 and Raptor, suppressing mTORC1-driven anabolic signalling — the energetically expensive growth programme targeted by caloric restriction and rapamycin in longevity research

The Complementarity: Retatrutide + MOTS-C

The two compounds in this stack are uniquely complementary because their mechanisms are parallel and non-overlapping:

  • Retatrutide acts centrally (hypothalamic appetite suppression), peripherally on pancreatic beta cells and incretin receptors (GIPR, GLP-1R, GCGR), and in adipose/liver tissue
  • MOTS-C acts within skeletal muscle mitochondria via AMPK — entirely independently of incretin signalling, GLP-1R, GIPR, or GCGR
  • Combined: appetite suppression + increased energy expenditure (Retatrutide) + enhanced peripheral glucose disposal and fat oxidation (MOTS-C) — addressing all three components of the energy balance equation simultaneously
  • MOTS-C’s muscle-protective AMPK activation may help preserve mitochondrial function and lean mass during the aggressive caloric deficit induced by retatrutide

MOTS-C Research References

  1. Lee C et al. “The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.” Cell Metab, 2015;21(3):443–454.
  2. Reynolds JC et al. “MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis.” Nat Commun, 2021;12:470.
  3. Kim KH et al. “MOTS-c peptide increases physical endurance and insulin sensitivity in aged mice.” Exp Mol Med, 2019;51:1–12.
  4. Lu H et al. “MOTS-c treatment attenuates inflammatory responses in the liver of aged mice.” Clin Interv Aging, 2019;14:1775–1782.

Stack Comparison: Metabolic Pathway Coverage

Parameter Retatrutide Alone MOTS-C Alone Combined Protocol
Appetite suppression Strong (GLP-1R/GCGR central) Minimal direct effect Strong (Retatrutide-driven)
Energy expenditure Moderate-strong (GCGR/BAT thermogenesis) Moderate (AMPK/β-oxidation) Additive — dual mechanism
Insulin sensitivity Improved (incretin-driven insulin secretion) Improved (GLUT4/AMPK — insulin-independent) Dual-pathway improvement
Mitochondrial function Limited direct effect Strong (retrograde mtDNA→nucleus signalling) Complementary, MOTS-C-driven
Hepatic steatosis Strong (GCGR-driven hepatic fat mobilisation) Moderate (AMPK → SREBP-1c suppression) Strong dual-mechanism clearance

All products in this bundle are supplied for research purposes only. Not for human consumption. Not evaluated by any regulatory authority.

Description

Metabolic Weight Loss Stack — Retatrutide & MOTS-C: The Most Advanced Dual-Pathway Metabolic Research Protocol

The Metabolic Weight Loss Stack pairs Retatrutide — the first GIP/GLP-1/glucagon triple agonist to demonstrate over 24% body weight reduction in Phase II clinical trials, surpassing all previously tested pharmacological agents — with MOTS-C, the mitochondria-encoded exercise mimetic that activates AMPK independently of the incretin axis. The combination creates a research model targeting metabolic dysfunction through two entirely separate molecular pathways: central neuroendocrine appetite suppression and energy expenditure (Retatrutide) and peripheral mitochondrial energy sensing and glucose disposal (MOTS-C).

Retatrutide (LY3437943): The Triple Incretin Agonist

What Is Retatrutide?

Retatrutide (development code LY3437943) is a synthetic acylated peptide analogue engineered by Eli Lilly & Company as a triple agonist of three metabolic hormone receptors simultaneously: the GIP receptor (GIPR), the GLP-1 receptor (GLP-1R), and the glucagon receptor (GCGR). It builds upon the dual GIP/GLP-1 mechanism of tirzepatide (Mounjaro/Zepbound) — itself the highest-performing approved weight loss drug — by adding glucagon receptor co-agonism, which expands metabolic effects to include dramatically increased energy expenditure and hepatic fat mobilisation, two mechanisms absent or weak in dual-agonist approaches.

Mechanism of Action

  • GLP-1R agonism: In the hypothalamic arcuate (ARC) and paraventricular nuclei (PVN), GLP-1R activation suppresses appetite by reducing neuropeptide Y (NPY) and agouti-related peptide (AgRP) — the primary orexigenic signals. In the gut, it slows gastric emptying, dramatically prolonging satiety duration. In pancreatic beta cells, it drives glucose-dependent insulin secretion with no hypoglycaemia risk at euglycaemia
  • GIPR agonism: GIP receptors in adipose tissue and the CNS contribute to the overall weight loss effect when co-stimulated with GLP-1R — a synergy not yet fully mechanistically elucidated, but consistently demonstrated to exceed either agonist alone. GIP also modulates bone metabolism, kidney function, and cardiovascular physiology
  • GCGR agonism — the key differentiator: Glucagon receptor activation drives hepatic glycogenolysis, increases fatty acid β-oxidation via CPT-1 upregulation, induces thermogenesis in brown adipose tissue (BAT) via UCP-1 (uncoupling protein-1), and activates a strong satiety signal through vagal afferents. Most critically, GCGR agonism significantly increases resting energy expenditure — addressing the metabolic adaptation (compensatory metabolic slowing) that limits long-term weight loss with appetite suppression alone
  • Hepatic fat reduction: Via GCGR-driven cAMP elevation in hepatocytes, retatrutide markedly reduces liver fat (steatosis) — making it simultaneously the most potent pharmacological research tool for both obesity and non-alcoholic steatohepatitis (NASH) models

Phase II Clinical Trial Data

Retatrutide has produced the most impressive Phase II weight loss data of any pharmacological agent in the history of obesity research:

  • NEJM Phase II trial (2023): Adults with obesity receiving retatrutide 12mg weekly achieved a mean weight reduction of 24.2% of body weight at 48 weeks — surpassing semaglutide (~15%), tirzepatide (~22%), and approaching outcomes previously observed only with bariatric surgery (Jastreboff AM et al., 2023 — N Engl J Med)
  • Dose-response relationship: 4mg group: −17.5% body weight; 8mg group: −22.8%; 12mg group: −24.2%. Responder rate (≥5% loss) at highest dose: >96%
  • Metabolic parameters: Fasting glucose −28 mg/dL, HbA1c −1.6%, triglycerides −30%, blood pressure −4/−3 mmHg; increased HDL cholesterol
  • Lean mass preservation: Unlike severe caloric restriction, retatrutide maintained lean-to-fat mass ratio — a critical research variable for understanding quality of weight loss vs. quantity
  • NASH model (Phase II): Significant reductions in liver fat content (MRI-PDFF) and fibrosis biomarkers, establishing retatrutide as the leading research compound for cardiometabolic-hepatic axis studies
  • Type 2 diabetes: Landmark Lancet 2023 trial: mean HbA1c reduction of 2.02% vs. 0.27% placebo at 24 weeks in T2D patients — with associated weight loss of 16.94% vs. 2.22% in placebo group (Rosenstock J et al., 2023 — Lancet)

Retatrutide Research References

  1. Jastreboff AM et al. “Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.” N Engl J Med, 2023;389(6):514–526.
  2. Rosenstock J et al. “Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes.” Lancet, 2023;402(10401):529–544.
  3. Coskun T et al. “LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss.” Cell Metab, 2022;34(9):1234–1247.
  4. Cusi K et al. “Retatrutide for NASH — Phase 2 results.” EASL Congress, 2023.

MOTS-C: The Mitochondrial AMPK Activator

What Is MOTS-C?

MOTS-C (Mitochondrial Open reading frame of the 12S rRNA type-c) is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA region — previously considered non-coding. Discovered in 2015 by Lee et al. at the University of Southern California, MOTS-C represents a fundamentally new paradigm in metabolic regulation: a retrograde mitochondrial-to-nuclear signal that coordinates systemic energy homeostasis in response to mitochondrial status. Its plasma levels decline with age and obesity, inversely correlating with insulin resistance, metabolic syndrome severity, and cardiovascular risk.

Mechanism of Action

  • AMPK activation via AICAR: MOTS-C inhibits MTHFD1 in the folate cycle, causing accumulation of AICAR (5-aminoimidazole-4-carboxamide ribonucleotide) — an endogenous AMP-mimetic that phosphorylates AMPK at Thr172 via LKB1 — functionally mimicking prolonged aerobic exercise at the molecular level
  • Direct nuclear translocation: Under metabolic stress, MOTS-C translocates directly to the nucleus where it interacts with ARE (antioxidant response elements) via Nrf2 and suppresses NF-κB inflammatory signalling — a mechanism entirely independent of AICAR/AMPK
  • GLUT4 translocation: AMPK-dependent phosphorylation of TBC1D1 and AS160 drives GLUT4 vesicle fusion with the sarcolemma — increasing skeletal muscle glucose uptake independently of insulin receptor activation
  • Enhanced β-oxidation: AMPK phosphorylates and inhibits ACC (acetyl-CoA carboxylase), reducing malonyl-CoA, relieving CPT-1 (carnitine palmitoyltransferase-1) inhibition, and dramatically increasing mitochondrial long-chain fatty acid import for β-oxidation
  • mTORC1 suppression via TSC2/Raptor: AMPK phosphorylates TSC2 and Raptor, suppressing mTORC1-driven anabolic signalling — the energetically expensive growth programme targeted by caloric restriction and rapamycin in longevity research

The Complementarity: Retatrutide + MOTS-C

The two compounds in this stack are uniquely complementary because their mechanisms are parallel and non-overlapping:

  • Retatrutide acts centrally (hypothalamic appetite suppression), peripherally on pancreatic beta cells and incretin receptors (GIPR, GLP-1R, GCGR), and in adipose/liver tissue
  • MOTS-C acts within skeletal muscle mitochondria via AMPK — entirely independently of incretin signalling, GLP-1R, GIPR, or GCGR
  • Combined: appetite suppression + increased energy expenditure (Retatrutide) + enhanced peripheral glucose disposal and fat oxidation (MOTS-C) — addressing all three components of the energy balance equation simultaneously
  • MOTS-C’s muscle-protective AMPK activation may help preserve mitochondrial function and lean mass during the aggressive caloric deficit induced by retatrutide

MOTS-C Research References

  1. Lee C et al. “The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.” Cell Metab, 2015;21(3):443–454.
  2. Reynolds JC et al. “MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis.” Nat Commun, 2021;12:470.
  3. Kim KH et al. “MOTS-c peptide increases physical endurance and insulin sensitivity in aged mice.” Exp Mol Med, 2019;51:1–12.
  4. Lu H et al. “MOTS-c treatment attenuates inflammatory responses in the liver of aged mice.” Clin Interv Aging, 2019;14:1775–1782.

Stack Comparison: Metabolic Pathway Coverage

Parameter Retatrutide Alone MOTS-C Alone Combined Protocol
Appetite suppression Strong (GLP-1R/GCGR central) Minimal direct effect Strong (Retatrutide-driven)
Energy expenditure Moderate-strong (GCGR/BAT thermogenesis) Moderate (AMPK/β-oxidation) Additive — dual mechanism
Insulin sensitivity Improved (incretin-driven insulin secretion) Improved (GLUT4/AMPK — insulin-independent) Dual-pathway improvement
Mitochondrial function Limited direct effect Strong (retrograde mtDNA→nucleus signalling) Complementary, MOTS-C-driven
Hepatic steatosis Strong (GCGR-driven hepatic fat mobilisation) Moderate (AMPK → SREBP-1c suppression) Strong dual-mechanism clearance

All products in this bundle are supplied for research purposes only. Not for human consumption. Not evaluated by any regulatory authority.

7 reviews for Metabolic Weight Loss Stack — Retatrutide & MOTS-C

  1. M
    Marta T. Verified

    Couldn’t be happier. Metabolic Weight Loss Stack is consistently dosed and the insulin sensitivity effects are exactly what the literature suggests.

    Verified purchase — Sweden

  2. S
    Sam N.

    Third order of Metabolic Weight Loss Stack and consistent quality every time. metabolic rate is the reason I keep coming back. Verified purchase from Belgium.

  3. S
    Sam N.

    Third order of Metabolic Weight Loss Stack and consistent quality every time. metabolic rate is the reason I keep coming back. Verified purchase from Belgium.

  4. J
    Julia W. Verified

    Positive experience. Metabolic Weight Loss Stack worked as expected for appetite control research. Delivery was smooth.

    Verified purchase — New Zealand

  5. J
    Julia R.

    Impressed by the professionalism. Metabolic Weight Loss Stack came with full COA, proper cold packaging, and metabolic rate results are measurable. Verified purchase from Australia.

  6. J
    Julia R.

    Impressed by the professionalism. Metabolic Weight Loss Stack came with full COA, proper cold packaging, and metabolic rate results are measurable. Verified purchase from Australia.

  7. L
    Lukas E. Verified

    Metabolic Weight Loss Stack is decent quality but I’ve seen better body fat reduction results with longer cycle durations. The purity seems fine.

    Verified purchase — United States

  8. L
    Lucas K. Verified

    Product quality seems fine but Metabolic Weight Loss Stack took longer than expected to show appetite control results. Will continue for another month.

    Verified purchase — Italy

  9. R
    Rachel E.

    Research grade as advertised. Metabolic Weight Loss Stack is exactly what I needed for weight loss research. COA provided without asking. Verified purchase from Italy.

  10. R
    Rachel E.

    Research grade as advertised. Metabolic Weight Loss Stack is exactly what I needed for weight loss research. COA provided without asking. Verified purchase from Italy.

  11. L
    Lucas M.

    Metabolic Weight Loss Stack arrived cold-packed, well within spec. My metabolic rate protocol has never been more effective. Verified purchase from Singapore.

  12. L
    Lucas M.

    Metabolic Weight Loss Stack arrived cold-packed, well within spec. My metabolic rate protocol has never been more effective. Verified purchase from Singapore.

  13. S
    Stephanie F.

    Happy with my Metabolic Weight Loss Stack purchase. Shipping was fast and weight loss protocol is progressing well. Great product overall. Verified purchase from Switzerland.

  14. S
    Stephanie F. Verified

    Happy with my Metabolic Weight Loss Stack purchase. Shipping was fast and weight loss protocol is progressing well. Great product overall. Verified purchase from Switzerland.

  15. R
    Rachel C.

    Good all round. Metabolic Weight Loss Stack appears to be dosed correctly based on observed metabolic rate effects. Would buy again. Verified purchase from Spain.

  16. R
    Rachel C. Verified

    Good all round. Metabolic Weight Loss Stack appears to be dosed correctly based on observed metabolic rate effects. Would buy again. Verified purchase from Spain.

  17. M
    Mason P.

    Metabolic Weight Loss Stack is doing the job. metabolic rate is the primary outcome I track and it is trending the right way after 6 weeks. Verified purchase from Spain.

  18. M
    Mason P.

    Metabolic Weight Loss Stack is doing the job. metabolic rate is the primary outcome I track and it is trending the right way after 6 weeks. Verified purchase from Spain.

  19. S
    Sophia H.

    Metabolic Weight Loss Stack is decent quality but I have seen better appetite control results with longer cycle durations. Purity seems fine. Verified purchase from Ireland.

  20. S
    Sophia H. Verified

    Metabolic Weight Loss Stack is decent quality but I have seen better appetite control results with longer cycle durations. Purity seems fine. Verified purchase from Ireland.

  21. A
    Amelia J. Verified

    Happy with my Metabolic Weight Loss Stack purchase. Shipping was fast and appetite control protocol is going well. Minor delay on tracking updates but product is great.

    Verified purchase — Netherlands

  22. M
    Mia J. Verified

    Metabolic Weight Loss Stack exceeded my expectations. Noticed body fat reduction improvements within the first two weeks. Reordering immediately.

    Verified purchase — New Zealand

  23. J
    Jessica K.

    Outstanding vendor. Metabolic Weight Loss Stack purity is verifiable, shipping was 2 days, and appetite control effects are undeniable at week 4. Verified purchase from United Kingdom.

  24. J
    Jessica K.

    Outstanding vendor. Metabolic Weight Loss Stack purity is verifiable, shipping was 2 days, and appetite control effects are undeniable at week 4. Verified purchase from United Kingdom.

  25. L
    Logan S. Verified

    As a researcher, I’m very particular about purity. The COA for Metabolic Weight Loss Stack checked out perfectly at 99.2%. Excellent product.

    Verified purchase — Germany

  26. M
    Marta S. Verified

    Happy with my Metabolic Weight Loss Stack purchase. Shipping was fast and metabolic rate protocol is going well. Minor delay on tracking updates but product is great.

    Verified purchase — Singapore

Add a review
All fields marked with an asterisk (*) are required

Related products

GH Axis Stack — HGH Somatropin & IGF-1 LR3

GH Axis Stack — HGH Somatropin & IGF-1 LR3

€ 60 – € 90 View Stack
Subscription
GHK-Cu 100mg — Monthly Subscription

GHK-Cu 100mg — Monthly Subscription

€ 59 / mo Add to Cart
Epithalon 10mg

Epithalon 10mg

€ 40 Add to Cart
NAD+ 100mg

NAD+ 100mg

€ 56 Add to Cart
Research Use Only — Important Notice
For in vitro research use only. Not for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease or condition. This product is supplied exclusively for qualified in vitro research. Purchasing this product confirms you are a qualified researcher and will use it accordingly. Learn about our quality standards →